Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer | OncLive

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

November 10, 2015

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Studies have shown that MSI-high tumors respond well to PD-LI inhibitors. Because of these findings, it is important that all patients be tested for MSI, even though only 4 to 5% will test positively, says Marshall.

In addition, evidence has shown that HER2 and BRAF mutations can also be targeted in colorectal cancer. There is an increased need to do broad molecular profiling to identify those mutations says Marshall.

<<<

View more from the 2015 CFS Annual Meeting


x